MABVAX THERAPEUTICS HOLDINGS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Gain on disposal of property and equipment
Stock-based compensation
Change in fair value of warrants
Issuance of restricted common stock for services
Amortization and accretion related to notes payable

Increase (decrease) in operating assets and liabilities:
Grant receivable
Other receivables
Prepaid expenses and other current assets
Prepaid expenses and other
Accounts payable
Accrued clinical operations and site costs
Accrued facility exit costs
Accrued facility exit costs and contingent lease termination fee
Purchases of investments
Maturities of investments
Proceeds from sale of property and equipment
Net cash provided by investing activities
Accrued compensation
Other accrued expenses
Net cash used in operating activities

Investing activities
Purchases of property and equipment
Proceeds from acquisition of Telik, Inc.
Net cash used in investing activities
Financing activities
Principal payments on financed insurance policies
Principal payments on capital lease
Principal payments on bank loan
Purchase of vested employee stock in connection with tax withholding obligation
Cash receipts from bank loan, net of financing costs
Proceeds from issuance of common stock and Series F Preferred Stock, net of costs, August 2016
Proceeds from issuance of Series H Preferred Stock, net of costs, May 2017
Proceeds from issuance of common stock and Series G Preferred Stock, net of costs, May 2017
Proceeds from issuance of common stock, net of costs, August 2017
Proceeds from exercise of stock options
Proceeds from issuance of preferred stock, common stock and warrants, net of issuance costs
Proceeds from exercise of MabVax Series B warrant
Proceeds from exercise of MabVax Series C-1 warrants
Proceeds from issuance of Series J Preferred Stock, net of costs, August 2017
Proceeds from issuance of common stock, net of costs, September 2017
Proceeds from issuance of common stock, net of costs, October 2017
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosure:
Cash paid during the period for income taxes
Cash paid during the year for income taxes
Cash paid during the year for interest on term note
Supplemental disclosures of non-cash investing and financing information:
Transfer of restricted investment in satisfaction of Porter Drive facility lease termination fee
Goodwill on acquisition of Telik, Inc.
Warrant liability upon acquisition of Telik, Inc.
Issuance of common stock for accounts payable
Deemed dividend on beneficial conversion feature for preferred stock
Purchase of equipment accrued in accounts payable
Fair value of warrants issued
Accretion of redemption value for Series A-1 and B preferred stock
Conversion of Series B redeemable preferred stock into common stock
Fair value of repricing of warrants issued in previous financing
Conversion of Series D preferred stock to common stock
Conversion of Series A-1 preferred stock into common stock
Exchange of Series A-1 preferred stock and warrants to common stock and Series D convertible preferred stock
Conversion of Series C-1 redeemable preferred stock into Series A-1 preferred stock
Conversion of Series D preferred stock into common stock
Conversion of Series A-1 preferred stock and warrants into common stock and Series D preferred stock
Acquisition of MabVax Therapeutics Holdings in relation to the merger
Warrants exercised to purchase common stock on a cashless basis to purchase 488,659 shares of common stock. See Note 7.
Exchange of Series B preferred stock and warrants to common stock and Series D convertible preferred stock
Warrants exercised to purchase common stock on a cashless basis
Elimination of warrant liability in exchange transaction
Financing transaction not yet paid
Conversion of Series C preferred stock to common stock
Property and equipment accrued in accounts payable
Conversion of Series I preferred stock to common stock
Conversion of Series J preferred stock to common stock
Conversion of Series K preferred stock to common stock
Exchange preferred stock Series F for Series L
Exchange preferred stock Series G for Series L
Exchange preferred stock Series H for Series L
Exchange preferred stock Series L for Series F, Series G and Series H
Deemed dividends on May 2017 inducement shares
Deemed dividends on August 2017 inducement shares
Deemed dividends on preferred stock exchange
Capital lease in connection with purchase of equipment

Comments